Wells Fargo raised the firm’s price target on Aflac (AFL) to $103 from $102 and keeps an Equal Weight rating on the shares. The firm notes Q1 came with weaker-than-expected sales in both Japan and the U.S. and a slip in the ESR. Sales continue to be weak, but management noted it expects the new cancer product to help boost JPY sales year-over-year and expects higher cancer sales in 2025 vs. 2024.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFL:
- Aflac Reports Q1 Earnings Amid Investment Losses
- Aflac’s Earnings Call: Growth Amid Financial Pressures
- AFLAC’s Strong Japanese Market Performance and Operational Efficiency in the U.S. Justify Buy Rating Despite EPS Miss
- Aflac price target raised to $96 from $95 at Barclays
- Closing Bell Movers: Microsoft and Meta rally after earnings